Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tafenoquine Under Fed Conditions for Plasmodium Vivax Radical Cure in Children
NCT07835321Phase 2Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tafenoquine in Plasmodium vivax malaria, sponsored by University of Oxford. Primary endpoints: Area under the curve from time zero to infinity at month 4, Maximum observed blood concentration at month 4 and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT07835321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835321.